Apimeds Pharmaceuticals US, Inc. 8-K

What Happened

• Apimeds Pharmaceuticals US, Inc. announced it received a notice from NYSE Regulation on April 17, 2026 that it is not in compliance with NYSE American listing rules because it has not timely filed its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025.
• NYSE gave the company an initial six‑month cure period (from April 17, 2026) to file the Form 10‑K; NYSE may, at its discretion, grant up to an additional six‑month extension depending on circumstances.
• The company said it expects to file the Form 10‑K by April 30, 2026 but noted there is no assurance that the filing will occur by that date. Apimeds’ common stock remains listed as APUS on NYSE American but will carry a “.LF” designation for late filing status. A trading halt from April 2, 2026 remains in effect. The company issued a press release on April 22, 2026 announcing the NYSE notice.

Key Details

• Date of NYSE notice: April 17, 2026.
• Subject: Failure to timely file Form 10‑K for year ended December 31, 2025.
• Cure period: 6 months from April 17, 2026 (possible discretionary extension up to another 6 months).
• Ticker and status: APUS on NYSE American with “.LF” late‑filing designation; trading halt effective April 2, 2026 remains in place.

Why It Matters

• For investors, a late Form 10‑K and NYSE non‑compliance notice can affect liquidity and market perception: the “.LF” tag signals reporting issues and the trading halt prevents normal share trading until lifted.
• The six‑month window gives the company a clear deadline to regain compliance by filing audited 2025 financials; failure to file could lead to further NYSE actions, including potential delisting.